Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,"Sunitinib, pazopanib","Renal cell carcinoma (RCC), advanced or metastatic, 2nd line after prior TKI treatment","Sunitinib, pazopanib",Recommended for decline,Community,Oncology Agents and Immunosuppressants
